57941-70-5Relevant academic research and scientific papers
Production device and method of high-content cyclic Grifola ester synthetic perfume (by machine translation)
-
Paragraph 0040-0043, (2020/01/25)
The invention discloses a production device of high-content cyadoop synthetic perfume and a method for, producing the cyclohexyloxy acetic acid through the saponification, and O - H acidification of, the high-content cyclic Grifola (, cyclohexanone). (by machine translation)
N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES
-
Page/Page column 83, (2019/01/21)
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2,L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to compounds for use in methods of inhibiting the ATF4 (activating transcription factor 4) pathway and treatment of disorders associated therewith, such as e.g. cancer, neurodegenerative diseases and many other diseases, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Preferred compounds of the invention are N-(3-(2-(4-chlorophenoxy) acetamido)bicyclo[1.1.1]pentan-l-yl)-2-cyclobutane-l-carboxamide derivatives and related compounds.
Method for synthesizing high-content galbanum oxyacetate fragrance
-
Paragraph 0040; 0042; 0049; 0051, (2019/12/25)
The invention discloses a method for synthesizing a high-content galbanum oxyacetate fragrance. The method replaces the Williamson reaction, and includes perform an O-H insertion reaction of ethyl diazoacetate and cyclohexanol under catalysis of a catalyst Rh2(OAc)4 to obtain ethyl cyclohexyloxyacetate, saponifying and acidifying to obtain cyclohexyloxyacetic acid, and esterifying with allyl alcohol to obtain galbanum oxyacetate. The method can greatly shorten the reaction time. In addition, a prepared solid acid catalyst Yb-MoO3/Al2O3-ZrO2 has the advantages of easy separation from a liquid phase reaction system, no corrosion on equipment and simple post-treatment, which overcomes the problems of corrosion of the existing liquid acid on the equipment and pollution of acid-containing wastewater on the environment; the catalyst has high selectivity, and can be applied at low temperatures, so as to save energy consumption, reduce occurrence of side reactions, and can greatly improve production efficiency, and the content of the prepared galbanum oxyacetate fragrance is as high as 99.6%; and the catalyst is good in thermal stability, and active components are not easy to lose, so thecatalyst has good reusability and is a new green catalytic material with great application potentials.
Carbene Transfer and Carbene Insertion Reactions Catalyzed by a Mixed-Ligand Copper(I) Complex
Brenna, Stefano,Ardizzoia, G. Attilio
, p. 3336 - 3342 (2018/07/13)
The catalytic activity of the mixed-ligand copper(I) complex [Cu(PPh3)2(κ2-O,O"-lact)] (1) {lact = l-(+)-lactate} has been investigated in carbene transfer and carbene insertion reactions. Complex 1 catalytically promoted the diastereoselective cyclopropanation of olefins in the presence of ethyl diazoacetate (EDA), under mild conditions, and with a low catalyst loading (1 mol-%). In the case of internal alkenes, a trans/cis ratio of up to 93:7 was reached. Moreover, compound 1 easily promoted the insertion of the carbene fragment deriving from the decomposition of ethyl diazoacetate into O–H (alcohols and phenols) and N–H (amine) bonds, with formation of the corresponding ethyl 2-alkoxyacetate, ethyl 2-phenoxyacetate, and ethyl 2-aminoacetate derivatives in good to high yields.
Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
-
Paragraph 0861, (2015/03/31)
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS
-
Paragraph 00504, (2014/02/15)
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
Heterocyclic compounds as P2X7 ion channel blockers
-
Page/Page column 78, (2010/02/10)
The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: 1 wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer''s disease, etc.
